VCEL — Vericel Corporation

Summary of Vericel Corporation Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: Record total revenue of $92.9 million, up 23% year-over-year, exceeding guidance.
• MACI Revenue: Achieved $84.1 million in Q4, also a 23% increase year-over-year and 51% sequential growth.
• Full Year Revenue: Total revenue for 2025 reached $276.3 million, surpassing guidance.
• Gross Margin: Q4 gross margin at 79%, with an adjusted EBITDA margin of 40%.
• Net Income: Grew nearly 60% to $16.5 million for the year.
• Cash Position: Ended 2025 with approximately $200 million in cash and no debt.

2. Strategic Updates and Business Highlights

• Sales Force Expansion: Successfully completed the MACI sales force expansion, enhancing market reach.
• MACI Ankle Clinical Study: Initiated the Phase III MACI Ankle MASCOT clinical study, targeting a market opportunity exceeding $1 billion.
• International Expansion: Plans to submit a marketing authorization application in the U.K. in mid-2026, with a potential launch in 2027.
• MACI Growth Drivers: Strong performance metrics with the highest number of MACI implants and surgeons since launch, supported by a robust pricing and reimbursement profile.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected total revenue of $316 million to $326 million, with MACI revenue projected at $280 million to $286 million.
• Burn Care Revenue: Anticipated at $36 million to $40 million for the full year, maintaining a run-rate approach.
• Q1 2026 Expectations: Forecasting MACI revenue of $54 million to $55 million and Burn Care revenue of $9 million to $10 million.

4. Bad News, Challenges, or Points of Concern

• Gross Margin Compression: Guidance for 2026 gross margin at 75%, down from 79% in Q4 2025, attributed to costs related to the new manufacturing facility and sales force expansion.
• Prudent Guidance: The 2026 MACI revenue growth guidance implies a slight slowdown to 18% from the previous year's growth rate of 20%, reflecting a cautious approach.
• Regulatory Delays: Potential delays in BARDA funding and regulatory approvals could impact revenue from NexoBrid and MACI Ankle.

5. Notable Q&A Insights

• Pricing vs. Volume Growth: Management acknowledged that both pricing and volume contributed to MACI's growth, with a strong emphasis on maintaining high prior authorization approval rates.
• Surgeon Adoption Dynamics: Approximately two-thirds of new MACI Arthro surgeons are existing users, indicating effective penetration within the current surgeon base.
• Sales Force Impact: While the expanded sales force is expected to enhance productivity, management has not baked significant improvements into the initial guidance, reflecting a cautious outlook.
• NexoBrid Adoption: Progress in reactivating dormant Epicel accounts and ongoing efforts to establish NexoBrid as a standard of care were highlighted, though the timeline for widespread adoption remains uncertain.

Overall, Vericel Corporation demonstrated strong financial performance in Q4 2025, with strategic initiatives poised to drive future growth, despite some caution in guidance and potential challenges ahead.